Encore Medical, a developer of cardiac implants, priced its IPO at $5 per share, aiming to raise $15 million.

Heart implant developer Encore Medical announced the terms of its initial public offering (IPO) on Tuesday. The company plans to issue 3 million shares at a price of $5 per share, raising $15 million. The company plans to list on the New York Stock Exchange under the ticker symbol "EMI". Encore Medical is headquartered in Eagan, Minnesota, USA. The company develops and manufactures septal occlusion devices, which are implantable products delivered through catheters used to repair certain heart defects, such as patent foramen ovale (PFO). The company's devices have been approved for sale in the European Union, and although it has not yet received regulatory approval to sell its devices in the United States, the company has received FDA approval to conduct trials in order to obtain market clearance. Data shows that the company generated revenue of $2 million in the 12 months ending September 30, 2025.